Our experience after 1765 intravitreal injections of bevacizumab: The importance of being part of a developing story

Seminars in Ophthalmology

Volumn 22, Issue 2, 2007, Pages 109-125

  Quiroz Mercado, Hugo ^a   Ustariz González, Orlando ^a   Martinez Castellanos, Maria A ^a   Covarrubias, Paola ^a   Dominguez, Francisca ^a   Sanchez Huerta, Valeria ^a  

^a Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

Author keywords

Anti angiogenesis; Choroidal neovascularization; Diabetic retinopathy; Retinal vascular occlusions; Retinal vasculopathies; Retinopathy of prematurity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CENTRAL SEROUS RETINOPATHY; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TELANGIECTASIA; VITRECTOMY; VITREORETINOPATHY; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; HUMANS; INFANT, NEWBORN; INJECTIONS; MACULAR DEGENERATION; RETINAL DISEASES; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; VITREOUS BODY;

EID: 34250353038     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530701420082     Document Type: Article

References (61)

1. Schlingemann R, Van Hinsbergh V. Role of vascular permeability factor vascular endothelial growth factor in eye disease. Br J Ophthalmol 1997; 81:501-12.
2. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways:therapeutic perspective. Clin Cancer Research 2006; 12:5018-22.
3. Stone J, Itim A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995; 15:4738-47.
4. Aiello LP. Angiogenic pathways in diabetic retinopathy. NEJM 2005; 353:839-41.
5. Murakami T, Suzuma K, Takagi H, Kita M, Ohashi H, Watanabe D, Ojima T, Kurimoto M, Kimura T, Sakamoto A., Unoki N, Yoshimura N. Time-lapse imaging of vitreoretinal angiogenesis originating from both quiescent and mature vessels in a novel ex vivo system. IOVS 2006; 47:5529-36.
6. Madan A. Angiogenesis and antiangiogenesis in the neonate relevance to retinopathy of prematurity. Neoreviews 2003; 4:456-364.
7. Hague S, MacKenzie IZ, Bicknell R, and Rees MCP. In-vivo angiogenesis and progestogens. Hum. Reprod. 2002; 17(3):786-93.
8. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005; 333:328-35.
9. Guerrero-Naranjo J, Bueno-García R, Quiroz-Mercado H, Ligett P, Alfaro III V, Reyna-Casteĺan E, Solis-Vivanco A. Security and side effects of Intravitreal Avastin using two methods of storage. Poster Number 4501/B447. ARVO 2006.
10. Barrera A, Cubas-Lorenzo V, Solis-Vivanco A, Quiroz-Mercado H, Fromow-Guerra J, Guerrero-Naranjo J. Contamination of bevacizumab (Avastin) Vials. Poster number 1749/B609. ARVO 2007.
11. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, Grillone LR, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, Ta C, Trese MT. Evolving guidelines for intravitreous injections. Retina 2004; 5 Suppl:S3-S19.
12. Liew G, Mitchell P, Gillies MC, Wong TY, Rosenfeld PJ, Brown DM, Schneider S. The MARINA and ANCHOR study groups: Ranibizumab for neovascular age-related macular degeneration. NEJM 2007; 356:747-50.
13. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. The ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. NEJM 2006; 355:1432-44.
14. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest.1995; 72:615-8.
15. Abaraham-Marin M, Cortez C, Quiroz-Mercado H, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2006; sep 28. Online.
16. Abraham-Marin ML, Hernandez-Rojas ML, Alvarez G, Cortez-Luna C, Morales-Canton V, Martinez-Castellanos M, Ustariz-Gonzalez O, Solis-Vivanco A, Reyna-Castelan E, Quiroz-Mercado H. Safety and Efficacy of Intravitreal Bevacizumab for Neovascular Age Related Macular Degeneration. Pilot Study. Poster Number 5239/B654. ARVO 2006.
17. Morales-Canton V, Abraham-Marin ML, Cortes-Luna C, Alvarez-Rivera G, Hernández-Rojas M, Quiroz-Mercado H. Intravitreal. bevacizumab therapy for neovascular age-related macular degeneration: A pilot study. Poster Number 129 Cannes Retina Festival 2006. ASRS and EVRS Meeting.
18. Fromow-Guerra JJ, Arevalo JF, Quiroz-Mercado H, Sanchez JG, Michel JE, Berrocal MH, Roca JA, Saravia MJ, Wu L. Pan-American Collaborative Retina Study Group(PACORES) Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Results of the Pan-American Collaborative Retina Study Group (PACORES) at 6-Months Follow-Up. Poster Number 4569/B250. ARVO 2007.
19. Ustariz-Gonzalez O, Abraham-Marin M, Gordon-Angelozzi M, Suarez-Licona A, Kon-Jara V, Torres-Soriano M, Salazar-Terán N, Dalma-Weiszhausz J, Quiroz-Mercado H. Treatment of Choroidal Neovascularization (CNV) AssociatedWith Age Related Macular Degeneration (AMD) With Photodynamic Therapy and Bevacizumab (Avastin) Inyection. Poster Number 290/B343. ARVO 2007.
20. Kon-Jara V, Torres-Soriano M, Diaz-Rubio J, Hernandez-Rojas M, Guerrero-Naranjo J, Fromow-Guerra J, Quiroz-Mercado H. Efficacy of RetreatmentsWith Bevacizumab in Choroidal Neovascularization Poster Number 5041/B189. ARVO 2007.
21. Martinez-Castellanos MA, Parrochia M, Quiroz-Mercado H. et al. Safety and Efficacy of Intravitreal Bevacizumab for Idiopathic Subfoveal Choroidal Neovascularization. Pilot Study. Poster Number 4282/B953 ARVO 2006.
22. Hernandez Ml, Dalma-Weiszhausz A, Solis-Vivanco A, Abraham-Marin M, Alvarez-Rivera G, Reyna-Castelan E, Ustariz-Gonzalez O, Martinez-Castellanos MA, Quiroz-Mercado H. Safety and Efficacy of Intravitreal Bevcizumab for subfoveal Choroidal neovascularization in pathologic Myopia. Pilot Study. Poster Number 4498/B444. ARVO 2006.
23. Hernadez-Rojas M, Dalma-Weiszhausz J, Quiroz-Mercado H, Fromow-Guerra J, Alvarez-Rivera G, Abraham-Marin ML, Solis-Vivanco A, Reyna-Castelan E, Guerrero-Naranjo JL, Jimenez-Sierra JM, Morales-Canton V. Safety and Efficacy of Intravitreal Bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Poster Number 330. Cannes Retina Festival 2006. ASRS and EVRS Meeting. Approved for publication in Retina.
24. Concha L, Kon V, Unzueta J, Navarro P, Arellanos L. Intravitreal Bevacizumab For The Treatment Of Neovasular Membrane In Patients With Intraocular Inflammation. Poster Number 5144/B292. ARVO 2007.
25. Fromow-Guerra JJ, Solis-Vivanco A, Reyna-Castelan E, Jimenez-Sierra JM, Martinez-Castellanos M, Quiroz-Mercado H. The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema. Poster Number 3852/B892. ARVO 2006.
26. Fromow-Guerra J, Reyna-Castelan E, Jimenez-Sierra JM, Solis-Vivanco A, Guerrero-Naranjo JL, Abraham-Marin ML, Hernandez-Rojas ML, Alvarez-Rivera G, Martínez-Castellanos MA, Quiroz-Mercado H. Efficacy of Intravitreal Bevacizumab for severe nonproliferative, proliferative diabetic retinopathy and active photocoagulated retinopathy. Poster Number 312. Cannes Retina Festival 2006. ASRS and EVRS Meeting.
27. Arevalo F, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH. Pan-American Collaborative Retina Study Group, PACORES. Primary intravitreal bevacizumab (Avastin) for diabetic Macular Edema: results of a multicenter collaborative study group. Paper presentation November 13, 2006, AAO, Las Vegas.
28. Arevalo J, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME. Pan-American Collaborative Retina Study Group (PACORES). Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results of the Pan-American Collaborative Retina Study Group at 6-Months Follow-Up. Poster Number 1412/B468. ARVO 2007.
29. Alvarez-Verduzco O, Torres-Soriano M, Reyna-Castelan E, Hernandez-Rojas M, Díaz-Rubio JL, García-Aguirre G, Guerrero-Naranjo JL, Jiménez-Sierra JM, Quiroz-Mercado H. Tractional Retinal Detachment after Intravitreal Injection of Bevacizumab in Proliferative Diabetic Retinopathy. Poster Number 4142/B304 ARVO 2007.
30. Perez Montesinos A, Torres-Soriano ME, Kon-Jara V, Diaz-Rubio J, Hernandez-Rojas M, Cubas-Lorenzo V, Martinez-Guzman O, Fromow-Guerra J, Quiroz-Mercado H, Jimenez-Sierra JM. Electrophysiologic Changes With Intravitreal Bevacizumab in Patients With Proliferative Diabetic Retinopathy. Poster Number 5041/B189. ARVO 2007.
31. Garcia-Aguirre G, Reyna-Castelan E, Torres M, Kon-Jara V, Quiroz-Mercado H. Intravitreal Bevacizumab vs. Panretinal Photocoagulation for the Treatment of Proliferative and Severe Non-proliferative Diabetic Retinopathy: A Contralateral Eye Study. Poster Number 3349/B496 ARVO 2007.
32. Alvarez-Rivera G, Guerrero-Naranjo JL, Perez-Reguera A, Moreno-Paramo D, Reyna E, Hernandez M, Solis A, Martinez-Castellanos MA, Quiroz-Mercado H. Is Intravitreous Bevacizumab (Avastin) an effective treatment for venous occlusions? Poster Number 4254/B925. ARVO 2006.
33. Guerrero-Naranjo JL, Morales-Canton V, Fromow-Guerra J, Alvarez-Rivera G, Solis-Vivanco A, Reyna-Castelan E, Jimenez-Sierra JM, Hernandez M, Ustariz-Gonzalez O. Intravitreal Bevacizumab (Avastin) as treatment for macular edema in vein oclussions. Poster Number 345. Cannes Retina Festival 2006. ASRS and EVRS Meeting.
34. Ustariz-González O, Suarez-Licona A, Quiroz-Mercado H, Guerrero-Naranjo JL, Perez-Reguera A, Moreno-Paramo D, Alvarez-Rivera G, Amaya-Espinoza A, Furno-Sola, F. Bevacizumab injection in Von Hippel Lindau Disease. Poster Number 4713/B1048. ARVO 2006.
35. Romo-Garcia E, Alvarez-Rivera G, Gordon M, Kon-Jara V, Martinez-Castellanos M, Moreno-Paramo D, Guerrero-Naranjo J, Quiroz-Mercado H. Is bevacizumab na affective treatrment for Coats disease? Poster Number 94/B210. ARVO 2007.
36. Torres ME, Ustáriz-Gonzáles O, Kon-Jara V, García-Aguirre G, Díaz-Rubio JL, Gordon-Angelozzi M, Solis-Vivanco A, Ober M, Guerrero-Naranjo JL, Quiroz-Mercado H. Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy Poster Number2894/B45. ARVO 2007.
37. Salazar-Teran N, Kon-Jara V, Ustariz-Gonzalez O, Reyna-Castelan E, Fromow-Guerra J, Quiroz-Mercado H. Does Avastin Change Evolution in Juxtafoveal Telangiectasias? Poster Number 4552/B233. ARVO 2007.
38. Quiroz-Mercado H, Travassos ACV, Martinez-Castellanos MA, Hernandez-Rojas M, Alvarez-Rivera G, Abraham-Marin M, Ustariz-Gonzalez O. Safety and efficacy for retinopathy of prematurity. Presented in Cannes Retina Festival September 13, 2006. ASRS and EVRS Meeting.
39. Martinez-Castellanos MA, Hernandez-Rojas M, Chan RVP, Quiroz-Mercado H. Safety and Efficacy Of Intravitreal Bevacizumab In Retinopathy Of Prematurity. Poster Number 85/B194. ARVO 2000.
40. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994; 35:3974-9.
41. Becerril V, Fernández G, Molina F. Growth factor levels and ROP. Ophthalmology 2005; 112(12):2238.
42. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vassels and has implications for retinopathy of prematurity. Nat Med 1995; 1:1024-8.
43. Stone J, Chang-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996; 37:290-9.
44. Bhisitkul, RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br.J. Ophthalmol. 2006; 90:1542-47.
45. Wu L, Quiroz-Mercado H, Roca J, Arevalo F, Farah M, Fromow J, Morales-Canton V, Jimenez J, Guerrero J. Pan American Collaborative Group. Safety of an intravitreal injection of bevacizumab (Avastin): Results of a multicenter Trial. Poster 5226/B641 ARVO 2006.
46. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo F, Eis Farah M, Berrocal MH, Rodriguez F, Roca JA, Maia M, Evans T, Sanchez JG. Pan-American Collaborative Retina Study Group, PACORES. Safety of an intravitreal injection of bevacizumab (Avastin): Results of a multicenter Trial Paper presentation November 13, 2006, AAO, Las Vegas.
47. Gordon M, Morales-Canton V, Solis-Vivanco A, Martinez-Castellanos M, Reyna E, Guerrero-Naranjo J, Quiroz Mercado H. Complication after intravitreal bevacizumab (Avastin): Analysis of 1910 injections. Poster Number 88/B197. ARVO 2007.
48. Hernández-Rojas ML, Jimenez-Sierra JM, Quiroz-Mercado H, Torres-Soriano ME, Diaz-Rubio JL, Cubas V, Martínez-Castellanos MA, Guerrero-Naranjo JL, Fromow-Guerra J, Morales.Canton V, Ochoa-Contreras D. Multifocal Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Poster Number 229. Cannes Retina Festival 2006. ASRS and EVRS Meeting.
49. Mng EW, and Adamis AP. Anti-VEGF Aptamer (Pegaptanib) therapy for ocular vascular diseases. Ann. N.Y. Acad. Sci. 2006; 1082(1):151-71.
50. Yokoi M, Yamagishi SI, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno S. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br. J. Ophthalmol. 2007; 91:397-8.
51. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br. J. Ophthalmol. 2006; 90:697-701.
52. Amrite AC, Ayalasomayajula SP, Cheruvu NPS, Kompella UB. Single periocular injection of Celecoxib-PLGA microparticles inhibits diabetes-induced elevations in Retinal PGE2, VEGF, and vascular leakage. IOVS 2006; 47:1149-60.
53. Jampol LM, Ebroon DA, Goldbaum MH. Peripheral proliferative retinopathies: an update on angiogenesis, etiologies and management. Surv Ophthalmol 1994; 38:519-40.
54. Saint-Geniez M, Maldonado AE, and D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest. Ophthalmol. Vis. Sci. 2006; 47(7):3135-42.
55. Marneros G, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, and Olsen BR. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 2005; 167(5):1451-59.
56. Reyna-Castelan E, Jimenez-Sierra J, Solis-Vivanco A, Fromow-Guerra J, Hernandez-Rojas M, Quiroz-Mercado H. OCT, visual outcome and angiographic analysis of choroidal neovascularization in six eyes with angioid streaks treated with a single intravitreal injection of bevacizumab. Poster 4287/B958 ARVO 2006.
57. Moreno-Páramo D, Perez-Reguera A, Meza-de Regil A, et al. Safety and Tolerance of bevacizumab injection in rabbit anterior chamber. Poster 3236/B706 ARVO 2006.
58. Ustariz-Gonzalez U, Martinez-Castellanos MA, Gordon M, Quiroz-Mercado H. Antiangiogenesis. Rev Mex de Oftalmol 2006; 80(5):268-71.
59. Wong D, Kyle G. Some ethical considerations for the "off label" use of drugs such as Bevacizumab. Br J Ophthalmol 2006; 90:1218-1219.
60. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90:1344-1349.
61. Rosenfeld, P. Retina Physician: Second Annual Physician Symposium. www.physician.com. Sept. 2006.